Association of an LMP2 polymorphism with acute myeloid leukemia and multiple myeloma. 2013

Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
Department of Biology, Section of Molecular Biology, Faculty of Arts and Science, University of Gaziantep, Gaziantep, Turkey E-mail : gerceker@gantep.edu.tr.

Hematological malignancies (HM) are a group of neoplasms derived from the cells of the bone marrow and lymphatic system. Genetic factors leading to susceptibility to HM have been investigated for years but little is known yet. Low molecular weight polypeptide (LMP) 2 and LMP7 genes are important subunits of the immunoproteasome and play significant role in antigen presentation. The polymorphisms of LMP genes have been reported to be risk factors for various types of diseases. The aim of this study was to investigate the association of LMP2 and LMP7 polymorphisms with the occurrence of particular types of HM. A total of 132 patients with HM and 130 control subjects were investigated. No significant difference was obtained in the distribution of genotype and allele frequencies of LMP7 gene in HM patients and the control group. On the other hand, the prevalence of LMP2-AA genotype was found to be higher in acute myeolid leukemia (AML) patients while it was significantly lower in multiple myeloma (MM) cases than in the control subjects. Our results suggested that LMP7 could not be a risk factor for susceptibility to HM, whereas LMP2 polymorphisms could play a role in the development of AML and MM.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009101 Multiple Myeloma A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. Myeloma, Plasma-Cell,Kahler Disease,Myeloma, Multiple,Myeloma-Multiple,Myelomatosis,Plasma Cell Myeloma,Cell Myeloma, Plasma,Cell Myelomas, Plasma,Disease, Kahler,Multiple Myelomas,Myeloma Multiple,Myeloma, Plasma Cell,Myeloma-Multiples,Myelomas, Multiple,Myelomas, Plasma Cell,Myelomas, Plasma-Cell,Myelomatoses,Plasma Cell Myelomas,Plasma-Cell Myeloma,Plasma-Cell Myelomas
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D005260 Female Females
D005787 Gene Frequency The proportion of one particular in the total of all ALLELES for one genetic locus in a breeding POPULATION. Allele Frequency,Genetic Equilibrium,Equilibrium, Genetic,Allele Frequencies,Frequencies, Allele,Frequencies, Gene,Frequency, Allele,Frequency, Gene,Gene Frequencies
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
January 2013, Annales de biologie clinique,
Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
October 2019, Blood,
Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
December 2006, Turkish journal of haematology : official journal of Turkish Society of Haematology,
Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
December 2000, Pediatric hematology and oncology,
Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
March 1991, Indian journal of cancer,
Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
May 1975, Human pathology,
Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
January 2003, [Rinsho ketsueki] The Japanese journal of clinical hematology,
Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
October 2023, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
January 2021, Annali dell'Istituto superiore di sanita,
Filiz Ozbas-Gerceker, and Nazli Bozman, and Selcuk Kok, and Mustafa Pehlivan, and Mehmet Yilmaz, and Sacide Pehlivan, and Sibel Oguzkan-Balci
October 2015, BMC cancer,
Copied contents to your clipboard!